Search This Blog

Thursday, March 6, 2014

Merck’s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Naïve Adults | Merck Newsroom Home

Merck’s Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Naïve Adults | Merck Newsroom Home

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.